NO752537L - - Google Patents
Info
- Publication number
- NO752537L NO752537L NO752537A NO752537A NO752537L NO 752537 L NO752537 L NO 752537L NO 752537 A NO752537 A NO 752537A NO 752537 A NO752537 A NO 752537A NO 752537 L NO752537 L NO 752537L
- Authority
- NO
- Norway
- Prior art keywords
- solution
- ions
- mol
- solution according
- endotoxin
- Prior art date
Links
- 239000000243 solution Substances 0.000 claims description 138
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 66
- 241000239218 Limulus Species 0.000 claims description 60
- 239000006166 lysate Substances 0.000 claims description 59
- 239000002158 endotoxin Substances 0.000 claims description 45
- 150000002500 ions Chemical class 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 15
- 230000003197 catalytic effect Effects 0.000 claims description 14
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- -1 Cleland's reagent Chemical class 0.000 claims description 10
- 229960002433 cysteine Drugs 0.000 claims description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 235000018417 cysteine Nutrition 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 8
- 229910001427 strontium ion Inorganic materials 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 229910001416 lithium ion Inorganic materials 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 claims description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 229910001422 barium ion Inorganic materials 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011565 manganese chloride Substances 0.000 claims description 2
- 235000002867 manganese chloride Nutrition 0.000 claims description 2
- 229940099607 manganese chloride Drugs 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 101100007699 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) creB gene Proteins 0.000 claims 1
- 101100402271 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) molB gene Proteins 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims 1
- 229910001626 barium chloride Inorganic materials 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229910001631 strontium chloride Inorganic materials 0.000 claims 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001698 pyrogenic effect Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003182 parenteral nutrition solution Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000239220 Limulus polyphemus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 241001529572 Chaceon affinis Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000239205 Merostomata Species 0.000 description 1
- 101100216185 Oryza sativa subsp. japonica AP25 gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/489,224 US4096091A (en) | 1974-07-17 | 1974-07-17 | Limulus lysate having improved capacity to precipitate in the presence of low endotoxin concentrations, and reconstituting solutions therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO752537L true NO752537L (ja) | 1976-01-20 |
Family
ID=23942932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO752537A NO752537L (ja) | 1974-07-17 | 1975-07-16 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4096091A (ja) |
| JP (1) | JPS5127994A (ja) |
| BE (1) | BE830917A (ja) |
| BR (1) | BR7504518A (ja) |
| CA (1) | CA1051327A (ja) |
| DE (1) | DE2530685C3 (ja) |
| ES (1) | ES439550A1 (ja) |
| FR (1) | FR2279105A1 (ja) |
| GB (1) | GB1502795A (ja) |
| IL (1) | IL47416A (ja) |
| NO (1) | NO752537L (ja) |
| SU (1) | SU603320A3 (ja) |
| ZA (1) | ZA753600B (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1522127A (en) * | 1976-07-23 | 1978-08-23 | Mallinckrodt Inc | Limulus amebocyte lysate reagent compositions |
| US4245044A (en) * | 1979-02-01 | 1981-01-13 | Cutter Laboratories, Inc. | Fat emulsion pyrogenicity test |
| JPS5642590A (en) * | 1979-09-14 | 1981-04-20 | Baxter Travenol Lab | Biological extracting liquid and production thereof |
| US4376819A (en) * | 1979-09-14 | 1983-03-15 | Baxter Travenol Laboratories, Inc. | Biological extracts and method for making same |
| US4279774A (en) * | 1979-11-13 | 1981-07-21 | Dynasciences Corporation | Method of removing lipid inhibitors from limulus amebocyte lysate |
| US4276050A (en) * | 1980-01-10 | 1981-06-30 | Abbott Laboratories | Method for systemic endotoxin detection |
| IL59383A (en) * | 1980-02-14 | 1983-03-31 | Technion Res & Dev Foundation | Micromethod for the determination of endotoxins with limulus amebocyte lysate |
| US4273557A (en) * | 1980-03-31 | 1981-06-16 | Mallinckrodt, Inc. | Limulus lysate procedure for determining endotoxins |
| US4301245A (en) * | 1980-05-29 | 1981-11-17 | Dynasciences Corporation | Chromogenic method of detecting endotoxins in blood |
| US4322217A (en) * | 1980-06-27 | 1982-03-30 | Mallinckrodt, Inc. | Process for preparing Limulus lysate |
| JP2957251B2 (ja) * | 1990-09-28 | 1999-10-04 | 生化学工業株式会社 | エンドトキシンの測定法 |
| WO2004094987A2 (en) * | 2003-04-18 | 2004-11-04 | Associates Of Cape Cod, Inc. | Kit for detecting endotoxin in aqueous solutions |
| US20050048655A1 (en) * | 2003-04-18 | 2005-03-03 | Novitsky Thomas J. | Kit for detecting endotoxin |
| PL3124976T3 (pl) * | 2015-07-28 | 2019-02-28 | F. Hoffmann-La Roche Ag | Ulepszony test na obecność bakteryjnej endotoksyny do oznaczania endotoksyn |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954663A (en) * | 1972-12-18 | 1976-05-04 | Teikoku Horinine Mfg. Co. Ltd. | Process for the preparation of Limulina lysate |
-
1974
- 1974-07-17 US US05/489,224 patent/US4096091A/en not_active Expired - Lifetime
-
1975
- 1975-06-03 ZA ZA00753600A patent/ZA753600B/xx unknown
- 1975-06-03 IL IL47416A patent/IL47416A/xx unknown
- 1975-06-04 CA CA228,463A patent/CA1051327A/en not_active Expired
- 1975-06-17 GB GB25667/75A patent/GB1502795A/en not_active Expired
- 1975-06-24 JP JP50079212A patent/JPS5127994A/ja active Pending
- 1975-07-02 BE BE157907A patent/BE830917A/xx unknown
- 1975-07-09 DE DE2530685A patent/DE2530685C3/de not_active Expired
- 1975-07-11 FR FR7521933A patent/FR2279105A1/fr not_active Withdrawn
- 1975-07-16 BR BR7504518*A patent/BR7504518A/pt unknown
- 1975-07-16 SU SU752155471A patent/SU603320A3/ru active
- 1975-07-16 NO NO752537A patent/NO752537L/no unknown
- 1975-07-17 ES ES439550A patent/ES439550A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2279105A1 (fr) | 1976-02-13 |
| IL47416A (en) | 1978-06-15 |
| GB1502795A (en) | 1978-03-01 |
| JPS5127994A (ja) | 1976-03-09 |
| ZA753600B (en) | 1976-04-28 |
| DE2530685B2 (de) | 1978-10-26 |
| DE2530685A1 (de) | 1976-01-29 |
| US4096091A (en) | 1978-06-20 |
| BE830917A (fr) | 1975-11-03 |
| BR7504518A (pt) | 1976-07-06 |
| IL47416A0 (en) | 1975-08-31 |
| ES439550A1 (es) | 1977-02-16 |
| SU603320A3 (ru) | 1978-04-15 |
| AU8198975A (en) | 1976-12-16 |
| CA1051327A (en) | 1979-03-27 |
| DE2530685C3 (de) | 1979-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO752537L (ja) | ||
| Hu et al. | Thermodynamic study of yeast phosphoglycerate kinase | |
| EP0569033B1 (en) | Pretreating reagent, method and kit and method of diagnosing infectious diseases | |
| CA1160549A (en) | Limulus amebocyte lysate procedure | |
| NO155785B (no) | Polymert viskositetsregulerende middel samt anvendelse derav i broennbehandlingsvaesker. | |
| US9459248B2 (en) | Immunoassay method for pro-gastrin-releasing peptide | |
| CN106867463A (zh) | 一种氧化石墨烯复合水凝胶基相变材料及其制备方法和应用 | |
| Greville et al. | Cation antagonism in blood coagulation | |
| EP0513361B1 (en) | Method of assaying endotoxin | |
| Mihalyi | The urea denaturation of fibrinogen | |
| US6270982B1 (en) | Methods and compositions for the detection of bacterial endotoxins | |
| Marquis et al. | Electric conductivity and internal osmolality of intact bacterial cells | |
| McKernan et al. | A basic derivative of dextran and its interaction with serum albumin | |
| EP0766087A2 (en) | Use of CO2 absorbant for stabilization of dried alkaline reagent in creatinine assay | |
| Libertini et al. | Effects of pH on the stability of chromatin core particles | |
| Eades | Freezing and recovering rare red blood cells using glycerol | |
| Bessho et al. | Differential extractability of creatine phosphate and ATP from cardiac muscle with ethanol and perchloric acid solution | |
| WO2023026725A1 (ja) | 細胞含有液用保存液及び細胞含有液用保存容器 | |
| US20040132207A1 (en) | Method for stabilizing blood, serum, or plasma specimen and container containing pH buffer agent | |
| US20030157556A1 (en) | Biological fluid stabilizing composition and method of use thereof | |
| US4302538A (en) | Buffer system in an anti-thrombin III test | |
| JP3531108B2 (ja) | 抗原抗体反応による被検物質の測定法及び試薬 | |
| CA1094930A (en) | Limulus amebocyte lysate reagent compositions | |
| JP2001019943A (ja) | 保冷剤 | |
| JPH0220537A (ja) | 多糖類組成物 |